Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Taste receptor type 2 member 10 (TAS2R10) is a G protein-coupled receptor (GPCR) primarily known for its role in detecting bitter-tasting compounds on the tongue, serving as a critical defense mechanism against the ingestion of toxic substances (1.1.1, 1.2.3). Beyond the oral cavity, TAS2R10 is widely expressed in extra-oral tissues such as the airway smooth muscle, gastrointestinal tract, and various cancer cells, where it mediates diverse physiological processes (1.1.3, 1.5.1). In the lungs, activation of TAS2R10 by bitter agonists like caffeine or strychnine induces potent bronchodilation, making it a promising therapeutic target for obstructive airway diseases like asthma and COPD (1.3.4, 1.5.1). In oncology, TAS2R10 has been identified as a potential tumor suppressor in neuroblastoma and pancreatic cancer, where its activation can inhibit cell proliferation and sensitize cells to chemotherapy by downregulating multidrug resistance transporters (1.5.1, 1.5.2). The receptor is characterized by its broad tuning, allowing it to recognize a diverse array of chemically distinct ligands, including natural toxins and pharmaceutical agents (1.2.3, 1.3.4). Consequently, TAS2R10 represents a versatile target for drug development, though its widespread expression necessitates careful consideration of off-target effects and systemic safety (1.5.1, 1.5.3).
Agonist-induced activation of the G protein-coupled signaling pathway, typically involving the G protein gustducin, which triggers phospholipase C beta-2 (PLCβ2) and subsequent intracellular calcium release (1.3.4, 1.4.1).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Taste receptor type 2 member 10 (TAS2R10) (TAS2R10).